

# Accepted Manuscript

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients with Acute Myeloid Leukemia: A Systematic Literature Review

Jill A. Bell, PhD, Aaron Galaznik, MD, Rachel Huelin, BA, Michael Stokes, MPH, Yelan Guo, MPH, Robert J. Fram, MD, Douglas V. Faller, MD, PhD

PII: S2152-2650(18)30131-9

DOI: [10.1016/j.clml.2018.05.003](https://doi.org/10.1016/j.clml.2018.05.003)

Reference: CLML 1107

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 6 February 2018

Revised Date: 2 April 2018

Accepted Date: 2 May 2018

Please cite this article as: Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV, Effectiveness and Safety of Therapeutic Regimens for Elderly Patients with Acute Myeloid Leukemia: A Systematic Literature Review, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.05.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



EFFECTIVENESS AND SAFETY OF THERAPEUTIC REGIMENS FOR  
ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA:  
A SYSTEMATIC LITERATURE REVIEW

**Target Journal:** *Clinical Lymphoma, Myeloma & Leukemia*

**Title:** Effectiveness and Safety of Therapeutic Regimens for Elderly Patients with Acute Myeloid  
Leukemia: A Systematic Literature Review

**Short Running Title:** SLR on Effectiveness and Safety of Treatment for Elderly AML Patients

**Authors:** Jill A. Bell<sup>a</sup>, PhD, [jill.bell@takeda.com](mailto:jill.bell@takeda.com)  
Aaron Galaznik<sup>a</sup>, MD, [aaron.galaznik@takeda.com](mailto:aaron.galaznik@takeda.com)  
Rachel Huelin<sup>b</sup>, BA, [rachel.huelin@evidera.com](mailto:rachel.huelin@evidera.com)  
Michael Stokes<sup>c</sup>, MPH, [michael.stokes@evidera.com](mailto:michael.stokes@evidera.com)  
Yelan Guo<sup>d</sup>, MPH, [yelan.guo@evidera.com](mailto:yelan.guo@evidera.com)  
Robert J. Fram<sup>a</sup>, MD, [robert.fram@takeda.com](mailto:robert.fram@takeda.com)  
Douglas V. Faller<sup>a</sup>, MD, PhD, [douglas.faller@takeda.com](mailto:douglas.faller@takeda.com)

**Institutions:**

<sup>a</sup> Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company  
Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.

<sup>b</sup> Evidera, 500 Totten Pond Road, Fifth Floor, Waltham, MA 02451, USA

<sup>c</sup> Evidera, 7575 Trans-Canada Highway, Suite 404, St-Laurent, Quebec, H4T 1V6, Canada

<sup>d</sup> Evidera, Metro Building, 6<sup>th</sup> Floor, 1 Butterwick, London, W6 8DL, United Kingdom

**Corresponding Author:** Jill A. Bell, PhD

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company  
Limited. 40 Landsdowne Street, Cambridge, MA, 02139, USA

Tel: +1-617-551-3968 Fax: +1-617-551-8675 Email: [jill.bell@takeda.com](mailto:jill.bell@takeda.com)

Download English Version:

<https://daneshyari.com/en/article/8615388>

Download Persian Version:

<https://daneshyari.com/article/8615388>

[Daneshyari.com](https://daneshyari.com)